Immunostimulants drugs - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.58 [0.07, 4.74]< 10%2 studies (2/-)69.5 %some concernnot evaluable moderatecrucial-
deaths 0.96 [0.83, 1.12]< 114%18 studies (18/-)67.9 %some concerncritical moderatecrucial1
deaths (time to event analysis only) 0.93 [0.47, 1.85]< 10%1 study (1/-)58.2 %lownot evaluable highcrucial-
clinical deterioration 0.48 [0.30, 0.78]< 10%3 studies (3/-)99.8 %some concernnot evaluable moderateimportant-
clinical improvement 1.17 [0.90, 1.52]> 149%7 studies (7/-)87.5 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 3.00 [1.03, 8.75]> 117%2 studies (2/-)97.8 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.76 [1.07, 2.92]> 128%3 studies (3/-)98.6 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 0.86 [0.58, 1.28]> 10%2 studies (2/-)23.1 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.28 [0.99, 1.66]> 144%7 studies (7/-)97.2 %some concernserious moderateimportant-
death or ventilation 1.00 [0.87, 1.15]< 139%4 studies (4/-)51.5 %some concernnot evaluable moderateimportant-
hospital discharge 1.23 [0.71, 2.15]> 135%3 studies (3/-)76.8 %some concernnot evaluable moderateimportant-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.97 [0.88, 1.08]< 10%7 studies (7/-)69.6 %some concernnot evaluable moderateimportant1
viral clearance 1.08 [0.43, 2.74]> 149%2 studies (2/-)56.8 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 0.81 [0.56, 1.18]> 10%1 study (1/-)13.7 %some concernnot evaluable moderateimportant-
viral clearance by day 14 10.23 [1.12, 93.35]> 10%1 study (1/-)98.0 %some concernnot evaluable moderateimportant-
viral clearance by day 7 2.33 [0.55, 9.83]> 10%1 study (1/-)87.5 %some concernnot evaluable moderateimportant-
ICU admission 0.43 [0.22, 0.85]< 143%6 studies (6/-)99.3 %some concernnot evaluable moderatenon important-
recovery 1.40 [0.70, 2.80]> 166%2 studies (2/-)83.0 %some concernnot evaluable moderatenon important-

safety endpoints 00

composite safety outcome 1.56 [0.78, 3.11]< 10%1 study (1/-)10.3 %lownot evaluable highimportant-
serious adverse events 0.96 [0.65, 1.41]< 10%5 studies (5/-)58.1 %some concernnot evaluable moderateimportant-
superinfection 0.18 [0.02, 1.59]< 10%1 study (1/-)93.8 %some concernnot evaluable moderateimportant-
adverse events 1.41 [0.74, 2.67]< 10%2 studies (2/-)14.6 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.